Fair question. I don’t blame Lilly for taking the stance that they are taking. In fact, I don’t think Lilly has much of a choice at this point. It’s interesting that Novo is already lowering expectations with their product by stating that inhaled insulin may not be a blockbuster product.
Eli Lilly is remaining optimistic about its yet-to-be-approved inhaled insulin despite the dramatic downfall of Pfizer's Exubera. But is Exubera's fall from grace an indication of things to come for inhaled diabetes treatments?
Eli Lilly is remaining optimistic about its yet-to-be-approved inhaled insulin despite the dramatic downfall of Pfizer's Exubera. But is Exubera's fall from grace an indication of things to come for inhaled diabetes treatments?
Comments